Strategic Planning Group LLC Raises Position in Eli Lilly and Company (NYSE:LLY)

Strategic Planning Group LLC raised its position in Eli Lilly and Company (NYSE:LLY) by 9.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 7,471 shares of the company’s stock after buying an additional 632 shares during the period. Eli Lilly and Company comprises about 1.2% of Strategic Planning Group LLC’s portfolio, making the stock its 25th largest holding. Strategic Planning Group LLC’s holdings in Eli Lilly and Company were worth $6,171,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of LLY. Garner Asset Management Corp grew its holdings in shares of Eli Lilly and Company by 2.3% during the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company’s stock worth $411,000 after purchasing an additional 12 shares during the period. FWG Holdings LLC lifted its position in Eli Lilly and Company by 0.6% during the fourth quarter. FWG Holdings LLC now owns 2,023 shares of the company’s stock valued at $1,640,000 after buying an additional 12 shares in the last quarter. Morling Financial Advisors LLC grew its stake in Eli Lilly and Company by 4.7% during the fourth quarter. Morling Financial Advisors LLC now owns 266 shares of the company’s stock worth $205,000 after buying an additional 12 shares during the period. Prestige Wealth Management Group LLC increased its position in shares of Eli Lilly and Company by 2.0% in the fourth quarter. Prestige Wealth Management Group LLC now owns 606 shares of the company’s stock worth $468,000 after acquiring an additional 12 shares in the last quarter. Finally, Applied Finance Capital Management LLC raised its stake in shares of Eli Lilly and Company by 1.4% in the 4th quarter. Applied Finance Capital Management LLC now owns 855 shares of the company’s stock valued at $660,000 after acquiring an additional 12 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Price Performance

Shares of LLY opened at $750.94 on Wednesday. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 52 week low of $677.09 and a 52 week high of $972.53. The stock has a 50 day moving average of $773.82 and a 200-day moving average of $799.64. The firm has a market cap of $711.69 billion, a price-to-earnings ratio of 64.13, a PEG ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same period in the prior year, the business earned $2.58 EPS. The business’s revenue was up 45.2% on a year-over-year basis. As a group, analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.80%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company’s dividend payout ratio (DPR) is 48.82%.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. The trade was a 14.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of a number of research reports. Wall Street Zen raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, May 30th. Guggenheim reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research report on Friday, May 23rd. HSBC downgraded shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and lowered their price objective for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. Morgan Stanley restated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Finally, Hsbc Global Res lowered Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research report on Monday, April 28th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus target price of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.